Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Roche Holding Ltd (OTC: RHHBY).

Full DD Report for RHHBY

You must become a subscriber to view this report.


Recent News from (OTC: RHHBY)

Kodiak Sciences files for initial public offering
Clinical-stage biopharmaceutical firm Kodiak Sciences has filed for its initial public offering . More news on: Roche Holding Ltd ADR, Regeneron Pharmaceuticals, Inc., Roche Holding Ltd, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: September, 07 2018 18:47
Guardant Health on deck for IPO
Redwood City, CA-based Guardant Health ( GH ) has filed a prospectus for a $100M IPO. More news on: Guardant Health, TrovaGene, Inc., Roche Holding Ltd ADR, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: September, 06 2018 10:55
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
F. Hoffmann-La Roche Ltd / Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New and ...
Source: Thomson Reuters ONE
Date: September, 06 2018 01:00
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
– New and updated pivotal data from the TECENTRIQ lung program, including overall survival (OS) and progression-free survival (PFS) results from Phase III IMpower133 study in extensive-stage small cell lung cancer – – New integrated pivotal results for entrectinib ...
Source: Business Wire
Date: September, 06 2018 01:00
Compugen, 'From Code To Cure': Becoming A Clinical-Stage Company
With a market cap of only $225 million (including $43 million in cash as of June 30th), Compugen Ltd. ( CGEN ) has the potential to deliver outsized returns for shareholders over the next 12 to 24 months. Since publishing my initial article on Compugen on SA on February 20, 2018, Compugen ...
Source: SeekingAlpha
Date: September, 05 2018 10:11
Biotech Analysis Central Pharma News: Pfizer Axes Drug, Merck's Approvals, Bayer's Green Light
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Pfizer Dumps DMD Drug After Trial Failures News: Recently, Pfizer ( PFE ) announced that it had failed two studies treating patients with duchenne...
Source: SeekingAlpha
Date: September, 04 2018 23:59
Big Pharma in the red after AstraZeneca lupus flop
Big Pharma is getting roughed up today. This morning, AstraZeneca ( AZN -1.7% ) announced that one of its main drivers of expected future growth failed a late-stage lupus study. More news on: AstraZeneca Group plc, Bausch Health Companies Inc., Roche Holding Ltd ADR, Healthcare stocks ne...
Source: SeekingAlpha
Date: August, 31 2018 13:41
Pfizer mid-stage flop with domagrozumab in DMD another setback for myostatin inhibitors - Endpoints News
Endpoints News' John Carroll reports that Pfizer's failure with domagrozumab in Duchenne muscular dystrophy (DMD) is another black eye for myostatin inhibitors for muscle wasting disorders. More news on: Novartis AG, Amgen Inc., Atara Biotherapeutics, Healthcare stocks news, Read mor...
Source: SeekingAlpha
Date: August, 30 2018 12:36
FDA OK's Bayer's Jivi for hemophilia A
The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, ...
Source: SeekingAlpha
Date: August, 30 2018 07:37
Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
F. Hoffmann-La Roche Ltd / Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announce...
Source: Thomson Reuters ONE
Date: August, 30 2018 01:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1431.2731.0931.4331.065,096,152
2018-12-1332.0231.9032.1631.811,924,837
2018-12-1231.9832.2632.4031.984,203,450
2018-12-1131.8531.6031.8531.38519,665
2018-12-1031.6931.5331.7131.16684,891

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141,147,6125,094,91322.5247Cover
2018-12-13261,3131,870,63413.9692Cover
2018-12-12467,3042,888,26516.1794Cover
2018-12-11111,830515,06421.7119Cover
2018-12-10192,416684,88928.0945Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RHHBY.


About Roche Holding Ltd (OTC: RHHBY)

Logo for Roche Holding Ltd (OTC: RHHBY)

Headquartered in Basel, Switzerland, Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue based cancer diagnostics, and a frontrunner in diabetes management. Founded in , Roche continues to search for better ways to prevent, diagnose and treat diseases and make sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life saving antibiotics, antimalarials and chemotherapy. In , the Roche Group employed about , people worldwide, invested . billion Swiss francs in R amp D and posted sales of . billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com

 

Contact Information

 

 

Current Management

  • Severin Schwan / CEO
  • Alan Hippe / CFO
  • Sonya Schwab / Administrator
  • Karl Mahler / Head of IR
  • Zoltan Molnar / Other
  • Christoph Franz / Chairman, Compensation Committee Member, Nominating Committee Member
  • Andre Hoffmann / Vice Chairman, Compensation Committee Member, Nominating Committee Member
  • John Irving Bell / Audit Committee Member
  • Julie Brown / Audit Committee Member
  • Paul Bulcke / Audit Committee Member
  • Claudia Sussmuth Dyckerhoff / Audit Committee Member
  • Anita Hauser /
  • Richard Lifton / Compensation Committee Member
  • Andreas Oeri /
  • Bernard Poussot / Compensation Committee Member
  • Severin Schwan /
  • Peter Voser / Compensation Committee Member

Current Share Structure

     


    Recent Filings from (OTC: RHHBY)

    Officer/Director Disclosure - Published Notifications on Management Transactions
    Filing Type: Officer/Director Disclosure - Published Notifications on Management TransactionsFiling Source: OTC Markets
    Filing Date: February, 27 2018
    Annual Report - Finance Report
    Filing Type: Annual Report - Finance ReportFiling Source: OTC Markets
    Filing Date: February, 01 2018
    Annual Report - Business Report
    Filing Type: Annual Report - Business ReportFiling Source: OTC Markets
    Filing Date: February, 01 2018
    Officer/Director Disclosure - Published Notifications on Management Transactions
    Filing Type: Officer/Director Disclosure - Published Notifications on Management TransactionsFiling Source: OTC Markets
    Filing Date: December, 18 2017

     

     


    Daily Technical Chart for (OTC: RHHBY)

    Daily Technical Chart for (OTC: RHHBY)


    Stay tuned for daily updates and more on (OTC: RHHBY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: RHHBY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RHHBY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RHHBY and does not buy, sell, or trade any shares of RHHBY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/